NCT02391792

Brief Summary

Microparticules (MPs) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. MPs are know recognized as a pool of bioactive messengers with merging role in pathophysiology of immune and cardiovascular diseases. MPs have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. This a prospective observational study of circulating MPs and blood coagulation in septic shock patients admitted in medical intensive care units (ICUs) of four tertiary hospitals at baseline (D1, D2, D3, D4, D7).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

September 4, 2014

Completed
7 months until next milestone

First Posted

Study publicly available on registry

March 18, 2015

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

August 24, 2016

Status Verified

August 1, 2016

Enrollment Period

7 years

First QC Date

September 4, 2014

Last Update Submit

August 23, 2016

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change from baseline in number and type of circulating microparticles at 7 days

    Baseline and 7 days

  • Change from baseline in blood coagulation markers at 7 days

    Baseline and 7 days

Study Arms (3)

patients

patients with septic shock

control

patients without septic shock

healthy volunteers

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

group patient: patients with septic shock group control: patients without septic shock

You may qualify if:

  • Septic shock (patients)
  • Without septic shock (control)
  • Informed consent

You may not qualify if:

  • Class IV heart failure
  • Child-plugh grade C cirrhosis
  • Cancer under active treatment
  • BMI\>35kg/m2
  • Moribund patient
  • DNR decision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nouvel Hopital Civil

Strasbourg, Alsace, 67091, France

RECRUITING

Related Publications (1)

  • Helms J, Severac F, Merdji H, Clere-Jehl R, Francois B, Mercier E, Quenot JP, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). Performances of disseminated intravascular coagulation scoring systems in septic shock patients. Ann Intensive Care. 2020 Jul 10;10(1):92. doi: 10.1186/s13613-020-00704-5.

Biospecimen

Retention: SAMPLES WITH DNA

blood

MeSH Terms

Conditions

SepsisShock, Septic

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Central Study Contacts

Ferhat MEZIANI, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
7 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 4, 2014

First Posted

March 18, 2015

Study Start

March 1, 2013

Primary Completion

March 1, 2020

Study Completion

March 1, 2020

Last Updated

August 24, 2016

Record last verified: 2016-08

Locations